DCTH Delcath stock news
On August 6, 2026, Delcath Systems Inc. (Nasdaq: DCTH) reported financial results for the second quarter of 2026, generating $11.4 million in revenue, primarily from HEPZATO KIT sales. This performance exceeded market expectations and reflected a significant increase in commercial adoption. The company reported a net loss of $6.8 million, an improvement from the prior year's $10.5 million loss. With 21 active treatment centers now operational and a cash reserve of $45.2 million, management indicated the company is well--positioned to fund operations into late 2027 while expanding its clinical pipeline.